Full Press Release Details
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS).
ZYME
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
Key Takeaway: Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)